Background {#Sec1}
==========

Infection with hepatitis C virus (HCV) leads to an asymptomatic acute stage. However, approximately 75% of acutely infected patients face a substantial risk of developing chronic HCV infection \[[@CR1]\]. During the 2 decades after infection, 27% develop liver cirrhosis, and 25% develop hepatocellular carcinoma (HCC) \[[@CR2], [@CR3]\]. Worldwide, an estimated 71 million people were living with chronic HCV infection (1.0% of the global population) \[[@CR4]\]. Whilst, in the European Union/European Economic Area (EU/EEA), it was estimated that more than 14 million people were living with chronic HCV infection, suggesting a relatively higher prevalence of 1.5% in this region \[[@CR4]\].

Given to the slow rates of liver disease progression, many countries are yet to experience the full burden of HCV-related disease \[[@CR5]\]. However, decade-long delays between infection and the expression of chronic liver disease or liver cancer made it difficult to link these diseases to earlier HCV infections. Reliable and timely prevalence data is therefore important to describe the current burden of the disease.

Most people infected with HCV remain unaware of their infection. The hidden burden estimated, based on limited data from the EU/EEA, shows that less than 15% of those chronically infected with HCV are aware of their diagnosis \[[@CR6]--[@CR8]\]. An anti-HCV antibodies serology test is recommended by the European Association for the Study of the Liver (EASL), as the first-line diagnostic test for HCV screening, which is evident of the past or current HCV infection \[[@CR9]\]. If the result is positive, then the current infection should be confirmed by a sensitive RNA test. Anti-HCV antibodies are detectable by enzyme immunoassay (EIA) in the vast majority of patients with an HCV infection. In addition, rapid diagnostic tests (RDTs) are also recommended in settings where there is limited access to laboratory infrastructure and testing or populations where access to RDTs would facilitate linkage to care \[[@CR10]\]. The primary goal of diagnostic testing is to identify and link infected individuals to appropriate treatment. Several modelling studies suggest that scaling up an HCV treatment can lead to substantial reductions in anti-HCV prevalence and reduce transmission \[[@CR11]--[@CR14]\]. The introduction of direct-acting antivirals (DAAs) has been a major breakthrough in the treatment of hepatitis C. However, the high acquisition costs of sofosbuvir-based regiments limit the access for patients and influence the costs of healthcare resource utilisation in hepatitis C \[[@CR15]\]. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and budget impact studies.

This study chose the most published reviews with a low risk of selection bias, according to an overview of systematic reviews on clinical burden of HCV infection \[[@CR16]\]. This study updated 2 previous systematic reviews undertaken respectively among the general population \[[@CR17]\] and high-risk groups \[[@CR18]\] in 2015. In Europe, the high-risk groups for the acquisition of HCV include people who inject drugs (PWID), men who have sex with men (MSM) and people in prison. The aim of this study was to update and expand the estimates for anti-HCV prevalence.

Objectives {#Sec2}
==========

The objective of the study is to update the anti-HCV prevalence (the serologic markers used as proxies for chronic infection in this study) among the general population and high-risk populations (MSM, prisoners, and PWID).

Methods {#Sec3}
=======

Date source and search strategy {#Sec4}
-------------------------------

Original research studies on the estimates of the prevalence among general and high-risk populations in the EU/EEA were retrieved from Medline and Embase for the period from 2015 to 2018. The search strategy used was consistent with previous reviews \[[@CR17], [@CR18]\] and is shown in Additional file [1](#MOESM1){ref-type="media"}. The search terms covered the following domains: disease-related (HCV infection), outcome-related (anti-HCV/HCV RNA prevalence), and geographic-related search terms (EU/EEA). Two separate searches were conducted to maximise the yield of the search, so that no population-specific search terms were included among the general population, MSM and prisoners. However, PWID-specific terms were included due to 2 reasons. The first being that previous reviews didn't conduct literature database searching, whilst the second was because the result of prevalence among PWID was only from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The relevant yield among PWID was much according to our preliminary search. To cover the complete time scope of the published studies the search for the general population, MSM and prisoners was limited to records between January 2015 and December 2018 and the search for PWID was limited between January 2009 and December 2018.

Inclusion/exclusion criteria and data extraction {#Sec5}
------------------------------------------------

The inclusion/exclusion criteria \[[@CR17], [@CR18]\] considered population, outcomes of interest, study designs, publication timeframe, and geographical scope. Studies were included if they: 1) reported anti-HCV seroprevalence among the general population, pregnant women, first-time blood donors, PWID, MSM, or prisoners; 2) measured the actual presence of viral markers (anti-HCV antibody in this study) in bodily fluid or dried blood spot samples in human subjects; 3) reported original data; 4) were published after 2015 to the present among the general population, pregnant women, first-time blood donors, MSM, or prisoners and published after 2009 to the present among PWID; 5) reported outcomes in one or more EU/EEA member states or any of their regions. Studies were excluded if they 1) targeted non-representative populations, e.g. the homeless, migrants, patients with specific diseases etc.; 2) did not report specified serological markers, or the reported study was not conducted on humans or only a self-reported/unconfirmed prevalence; 3) reported modelled or extrapolated data only, or opinion papers, editorials, guidelines or recommendations, correspondence articles, systematic reviews or meta-analysis; 4) were published out the targeted timeframe; 5) reported data on non-EU/EEA countries only. More details on the inclusion/exclusion criteria are shown in Additional file [1](#MOESM1){ref-type="media"}.

The extraction form included year, country, characteristics of the analysed population, the sampling method, laboratory test used, participation rate, number of participants, and anti-HCV results. For studies reporting the prevalence in MSM, data on HIV sero-status was also extracted.

Quality assessment for risk of selection bias {#Sec6}
---------------------------------------------

Each included study was evaluated for risk of selection bias using frameworks developed by Hofstraat et al. and Falla et al. \[[@CR17], [@CR18]\]. For studies among the general population and prisoners, three domains were included: whether estimates were standardised by age and sex, the representativeness of sampling (e.g. random vs. convenience sampling) and geographical coverage. For PWID and MSM studies, just one domain was included: geographical coverage. Points were awarded in each domain for a lower risk of bias, and a total score calculated by summing the values in each domain. An estimate among the general population and prisoners was considered of low risk when it reached a study quality score ≥ 4. A low risk estimate of prevalence in PWID and MSM was defined as a study quality score ≥ 1.

Data analysis {#Sec7}
-------------

All included studies were summarised together in a narrative form and in summary tables that tabulate the important description of the study population, recruiting period, results and study quality. According to the results of the systematic review previously performed, an algorithm was applied to different populations separately \[[@CR17], [@CR18]\]: If a single low risk of selection bias prevalence estimate was available for a country, this was used. If a low risk of selection bias estimate was not available, high risk of selection bias estimates were used (these were pooled when possible). Data per country were pooled according to the standard error and sample size. Then 95% confidence intervals were calculated by the estimated average and pooled sample size. Results of subgroup analyses of age-specific, gender-specific, or injecting risk-specific prevalence were reported. Results from previous reviews and the updated searches were compared per country among different populations, respectively.

The overall population was categorised into 2 groups: (1) the general population, inclusive of susceptible population with no recognised risk factors for reinfection (communities, screening participants, pregnant women, and first-time blood donors); (2) high-risk populations, inclusive of susceptible MSM, prisoners, and PWID. The majority of EU/EEA countries offer antenatal HCV screening and first-time blood donors screening. These 2 subgroups among the general population are the most complete population prevalence source and used as a proxy population \[[@CR17]\]. However, we conducted separate analysis between pregnant women, first-time blood donors and other general populations because the previous systematic review reported that they are not representative enough.

Some estimates among the general population included exclusively multiple subgroups, overlapping with high-risk populations. When pooled together, however, the subgroup data were excluded and pooled with the relevant high-risk populations based on the results of quality assessment.

Results {#Sec8}
=======

Literature search retrievals {#Sec9}
----------------------------

The search for data on anti-HCV prevalence in the general population and MSM, and people in prison and PWID identified 2790 and 1081 citations, respectively. After the title/abstract screening, 73 articles for the general population with 2 subgroups and 26 articles for PWID were included. Following the full text screening of these 99 papers, 53 publications were considered not relevant. Finally, 46 publications were included in the review of prevalence data, with 11 publications used for the estimate of the general population, 7 for pregnant women, 2 for first-time blood donors, 3 for MSM, 6 for prisoners and 17 for PWID (Fig. [1](#Fig1){ref-type="fig"}). The results of quality assessment for risk of selection bias are shown in Additional file [1](#MOESM1){ref-type="media"}.Fig. 1Flow diagram of the study selection process

Anti-HCV prevalence among the general population in EU/EEA {#Sec10}
----------------------------------------------------------

### General population {#Sec11}

The anti-HCV general population prevalence estimates were found for 7 of the 34 countries in our review, ranging from 0.54 to 1.50% by country (Table [1](#Tab1){ref-type="table"}). More than one estimate was available for 4 countries of the 7 countries covered, with the most estimates for Spain (*n* = 3). Eight low risk of selection bias estimates from 5 countries (Czech Republic, Ireland, Italy, Portugal and Spain) were available. Multiple low-risk of selection bias estimates were available for a pooled estimate in Italy (*n* = 2). A relatively high anti-HCV prevalence was found in the Czech Republic (1.67%), Poland (1.50%) and Italy (1.37%). The estimate for Poland, however, is based on one single study with a high risk of selection bias (score = 2). The other article reporting the prevalence estimate on the general female population in Poland was not pooled. Three estimates were available for Spain, of which only one was of low risk of selection bias and reported an anti-HCV prevalence of 1.11%. One article reported 1.14% in the Callosa D'En Sarrià and Valencian Region. The other one reported 0.60% in the general female population. Subgroup analysis of age-specific prevalence was available for Italy \[[@CR22], [@CR23]\] and Poland \[[@CR24]\]. In Italy \[[@CR22], [@CR23]\], the prevalence of HCV increased with an increasing birth cohort (0.20% in subjects born after the year 1984, 1.20% in those born in 1975--1984, 1.60% in those born in 1965--1974, 1.20% in those born in 1955--1964, 2.20% in those born in 1945--1954, 7.00% in those born in 1935--1944, and 4.20% in those born before the year 1953). In Poland \[[@CR24]\], a higher prevalence was found in the post-reproductive population with an age more than 45 years (1.50% in 15--24 years, 1.20% in 25--34 years, 1.60% in 35--44 years, 2.90% in 45--54 years and 2.60% in 55--64 years).Table 1Summary of results from studies reporting anti-HCV prevalence in the general populationAuthor, yearCountryRecruiting periodPopulation as reportedAge, mean (SD)Sample sizeAnti-HCV prevalence (%) (95% CI)Risk of selection biasViejo, 2018 \[[@CR19]\]SpainFebruary--April 2017The general adult population living in the health area of Callosa D'En Sarrià47.5 (−)26371.14 (0.73--1.55)High riskLavin, 2017 \[[@CR20]\]Spain2015--2016Spanish adult population--68391.11 (−)Low riskQuesada, 2015 \[[@CR21]\]Spain1994--2005Women from the general population in different geographical areas worldwide40.0(15.6)3140.60 (0.20--2.50)High riskAndriulli, 2018 \[[@CR22]\]Italy2015The general population--49072.30 (−)Low riskMorisco, 2017 \[[@CR23]\]ItalyMay 14A random 1:3 systematic sample of the adult general population of Naples49.9(5.00)13153.00 (2.10--4.00)Low riskWalewska-Zielecka, 2017 \[[@CR24]\]Poland2004--2014Patients who had been tested for anti-HCV at least once in the period from 2004 to 201434.4(8.6)618051.50 (−)High riskClifford, 2017 \[[@CR25]\]Poland2004--2009The general female population37.0(−)9090.80 (0.30--1.60)High riskGarvey, 2017 \[[@CR26]\]IrelandApril--June 2014 and November 2015--February 2016The adult population in Ireland with probability proportional to the general population age-sex distribution--37590.98 (−)Low riskChlibek, 2017 \[[@CR27]\]Czech RepublicFebruary 2015--September 2015The adult general population47.1(17.1)30001.67 (1.27--2.19)High riskCarvalhana, 2016 \[[@CR28]\]PortugalApril 2012--December 2014Adults from primary care settings in mainland Portugal50.2(18.3)16270.54 (0.20--0.90)Low riskPlompen, 2015 \[[@CR29]\]Netherland−The general Dutch elderly population69.5(9.0)60360.56 (−)High risk

### Pregnant women {#Sec12}

An estimate of antenatal anti-HCV prevalence was found for 6 of the 34 countries in our review, ranging from 0.10 to 1.32% by country (Table [2](#Tab2){ref-type="table"}). More than one estimate was available only for the UK of the 6 countries covered (*n* = 2). Five low risk of selection bias estimates from 5 countries (Poland, Slovenia, Spain, Sweden and the UK) were available. Only the estimate of Italy was of high risk of selection bias. Relatively high anti-HCV prevalence was found in Poland (1.32%) and Spain (0.55%). Relatively low prevalence was reported in the UK (0.10%). The other article reporting the prevalence estimate on women who attended antenatal clinics in London (0.5%) was not pooled given to the potential geographic bias. Subgroup analysis of age-specific prevalence was available for the UK \[[@CR30], [@CR31]\], Poland \[[@CR34]\] and Slovenia \[[@CR32]\]. In the UK \[[@CR30], [@CR31]\], the antenatal anti-HCV prevalence increased with increasing age in mothers born in the UK (0.00% in younger than 21 years, 0.00% in 21--25 years, 0.00% in 26--30 years, 0.03% in 31--35 years and 0.07% in older than 35 years) and Asia-Pacific (0.00% in younger than 21 years, 0.00% in 21--25 years, 0.12% in 26--30 years, 0.16% in 31--35 years and 0.49% in older than 35 years), but peaked in mothers of 26--30 years (0.85%) born in Eastern Europe (0.00% in younger than 21 years, 0.22% in 21--25 years, 0.16% in 31--35 years and 0.29% in older than 35 years). No statistically significant differences in antenatal anti-HCV prevalence between age groups were reported in Poland (0.90% in 15--24 years, 0.70% in 25--34 years and 0.80% in 35--44 years) \[[@CR34]\] and Slovenia (0.00% in younger than 20 years, 0.07% in 20--29 years and 0.05% in older than 30 years) \[[@CR32]\].Table 2Summary of results from studies reporting anti-HCV prevalence in pregnant women and first-time blood donorsAuthor, yearCountryRecruiting periodPopulation as reportedAge, mean (SD)Sample sizeAnti-HCV prevalence (%) (95% CI)Risk of selection biasPregnant women Orkin, 2016 \[[@CR30]\]UK2013Women who attended antenatal clinics during 2013 at 2 London hospitals--10000.50 (0.06--0.94)High risk Cortina-Borja, 2016 \[[@CR31]\]UK1 April--30 June 2012Women delivering live-born infants in the North Thames region in England--314670.10 (0.07--0.14)Low risk Kopilovic, 2015 \[[@CR32]\]Slovenia1999, 2003, 2009 and 2013Pregnant women--318490.13 (0.09--0.17)Low risk Lembo, 2017 \[[@CR33]\]ItalyJanuary 2010--December 2015Pregnant women consecutively admitted to the Division of Obstetrics and Gynaecology of the University Hospital of Messina, Italy--51840.20 (−)High risk Walewska-Zielecka, 2016 \[[@CR34]\]Poland2004--2014Pregnant women in Poland33.4(7.9)422741.32 (−)Low risk Millbourn, 2017 \[[@CR35]\]SwedenOctober 2013--March 2015 andOctober 2013--February 2016Every pregnant woman and her partner in Orebro county and in Southern part of Stockholm (288,000 and 300,000 inhabitants, respectively)--213790.20\* (−)Low risk Munoz-Gamez, 2016 \[[@CR36]\]SpainJanuary--October 2015Pregnant women in Spain--−0.55 (0.55--0.77)Low riskFirst-time blood donors Velati, 2018 \[[@CR37]\]ItalyJanuary 2009--December 2015Voluntary, unpaid first-time donors--19346120.09 (0.08--0.09)Low risk Politis, 2018 \[[@CR38]\]Greece2010--2016Blood donor--−0.03 (−)High risk\*calculated based on available data

### First-time blood donors {#Sec13}

An estimate of anti-HCV prevalence in first-time blood donors was available for only 2 of the 34 countries in our review, with Greece reporting 0.03% and Italy reporting 0.09% (Table [2](#Tab2){ref-type="table"}). One high risk of selection bias estimate for Greece and one low risk of selection bias estimate for Italy were available. There is no subgroup analysis among first-time blood donors reported.

Anti-HCV prevalence among high-risk populations in the EU/EEA {#Sec14}
-------------------------------------------------------------

### MSM {#Sec15}

An estimate of anti-HCV prevalence in MSM was found for 3 of the 34 countries in our review (Table [3](#Tab3){ref-type="table"}). Furthermore, the MSM was divided into 2 categories: HIV-positive MSM and HIV-negative MSM. The prevalence in HIV-positive MSM covered 3 countries, ranging from 1.80% (the UK) to 7.10% (the Netherlands). The other country, France, reported 5.10%. The prevalence in HIV-negative MSM covered 2 countries, ranging from 0.20% (the UK) to 1.80% (France). Two low risk of selection bias estimates from 2 countries (the UK and France) were available. Only the estimate of the Netherlands was of high risk of selection bias. There is no subgroup analysis among MSM reported.Table 3Summary of results from studies reporting anti-HCV prevalence in MSM and prisonerAuthor, yearCountryRecruiting periodPopulation as reportedAge, mean (SD)Sample sizeAnti-HCV prevalence (%) (95% CI)Risk of selection biasMSM Ireland, 2017 \[[@CR39]\]UK28 February - 15 December 2014MSM attending 4 genitourinary medicine clinics in Manchester--HIV+:735HIV-:8551.80 (−)0.20 (−)Low risk Vanhommerig, 2013 \[[@CR40]\]Netherland2009--2012HIV-infected MSM during 5 waves of anonymous surveys at Amsterdam STI clinic--4397.10 (−)High risk Cotte, 2018 \[[@CR41]\]FranceJanuary 2016 to May 2017HIV+, HCV-negative MSM with serological follow-up in 2016--HIV+:13051HIV-:9305.10 (−)1.80 (−)Low riskPrisoner Ekeke, 2018 \[[@CR42]\]UKDecember 2015-February 2017Prisoners entered Pentonville prison--13247.00 (−)High risk Patel, 2016 \[[@CR43]\]UK−Inmates in a medium security prison--16033.75 (−)High risk Casella, 2016 \[[@CR44]\]Portugal2014 and 2016Inmates of 2 male prisons in the centre of Portugal (Pinheiro da Cruz and Setubal)--8238.00 (−)High risk Liberal, 2017 \[[@CR45]\]PortugalJanuary--AprilInmates from one of the largest prisons in Portugal--120815.70\* (−)High risk Svendsen, 2017 \[[@CR46]\]NorwaySeptember 2015At-risk populations in Trondheim, Norway--30441.00 (−)High risk Lerena, 2016 \[[@CR47]\]Spain−Inmates in a Northern region of Spain(Cantabria) with 600 k inhabitants and focused on the regional long-stay prison of El Dueso--43616.00 (−)High risk

### Prisoners {#Sec16}

An estimate of anti-HCV prevalence was found for 4 of the 34 countries in our review, ranging from 7.00 to 41.00% by country (Table [3](#Tab3){ref-type="table"}). More than one estimate was available for the UK (*n* = 2) and Portugal (*n* = 2) of the 4 countries covered. All estimates in prisoners were of high risk of selection bias. All studies were single-centre in a regional level, except the one in Portugal, which was a multi-centre. Three studies reported a ratio of sex with more males than females. The other 3 studies did not report a ratio of sex. None of these 6 studies reported data on age. The studies in Portugal and Spain used exhaustive sampling in the included prison. Sampling method for the other studies was not reported. An extremely high prevalence was found in Norway (41.00%). However, this estimate was from a single high risk of selection bias study with a small sample size (*n* = 62). There is no subgroup analysis among prisoners reported.

### PWID {#Sec17}

An estimate of anti-HCV prevalence was found for 13 of the 34 countries in our review, ranging from 7.90 to 82.00% by country (Table [4](#Tab4){ref-type="table"}). More than one estimate was available for 4 of 13 countries covered, with the most estimates for the UK (*n* = 3). Nine low risk of selection bias estimates from 6 countries (Croatia, Hungary, Germany, France, Spain and the UK) were available. Multiple low risk of selection bias estimates were available for a pooled estimate in the UK (*n* = 3) and France (*n* = 2). A high anti-HCV prevalence was found in Sweden (82.00%) and Spain (72.00%). A relatively low prevalence was reported in the UK (36.50%) and Croatia (34.04%). However, the estimate in Spain was of high risk of selection bias (score = 0). One article in the UK covered the vulnerable population in London, including both PWID and prisoners. Based on the results of quality assessment (score = 1), this result was also pooled into the estimate. Another article in the UK reported only a subgroup prevalence based on the years when the subjects were born. However, the exact estimate of subjects who were born in the early 1990s was not available. Only estimates from the subjects born after 2000 were pooled. The article in Croatia reported separated prevalence among PWID in the cities of Zagreb, Split and Rijeka. Data from the 3 cities in this article were pooled. The same situation came up in Germany with separated prevalence estimates in native German and former Soviet Union migrants, which were in the same article and pooled together. Subgroup analysis of age-specific prevalence was available for France \[[@CR54]\] and Greece \[[@CR56]\] and subgroup analysis of injection risk-specific prevalence was available for Greece \[[@CR56]\], the UK \[[@CR50]\], Hungary \[[@CR58]\], and Spain \[[@CR52]\]. Anti-HCV prevalence among PWID increased with increasing age in France (15.00% in 18--35 years and 56.00% in 35--65 years) \[[@CR54]\] and Greece (52.60% in 15--24 years and 90.00% in older 65 years) \[[@CR56]\]. Long-term injectors (those who had been injecting for more than 5 years) reported higher anti-HCV prevalence than new injectors in Greece (85.70% vs. 34.00%) \[[@CR56]\], the UK (60.00% vs. 38.00%) \[[@CR50]\] and Spain (77.10% vs. 59.40%) \[[@CR52]\]. In Hungary \[[@CR58]\], the anti-HCV prevalence in new psychoactive substances (NPS) injectors became the highest among the three injector groups (74.00% in NPS injectors, 59.00% in amphetamine injectors and 55.00% in opioid injectors).Table 4Summary of results from studies reporting anti-HCV prevalence in PWIDAuthor, yearCountryRecruiting periodPopulation as reportedAge, mean (SD)Sample sizeAnti-HCV prevalence (%) (95% CI)Risk of selection biasAisyah, 2018 \[[@CR48]\]UK2011--2013Vulnerable populations in London--120711.40 (--)Low riskHope, 2016 \[[@CR49]\]UK1992--2013Image and performance-enhancing drugs injectors in England and Wales--3437.90 (--)Low riskHope, 2015 \[[@CR50]\]UKSince 1990PWID from needle and syringe, opiate substitution treatment except for Scotland--12341.70 (--)Low riskValencia, 2018 \[[@CR51]\]SpainJanuary 2013--December 2016PWUD who actively consumed heroin and/or cocaine, either smoked or injected41.3(8.50)94633.30 (--)High riskFolch, 2016 \[[@CR52]\]Spain2010--2011PWID in harm reduction centres in Catalonia--75472.00 (68.8--75.2)Low riskLeon, 2016 \[[@CR53]\]France2004 and 2011IDU--124243.40 (39.00--47.90)Low riskWeill-Barillet, 2016 \[[@CR54]\]France2011Drug users having injected or snorted drugs at least once in their life39.0(−)96064.00 (59.20--68.20)Low riskSypasa, 2017 \[[@CR55]\]Greece2012--2013During an HIV outbreak among PWID in Athens--43149.90 (45.00--54.70)High riskSheka, 2014 \[[@CR56]\]GreeceJanuary 1997--December 2007Intravenous drug users who attended the Greek Organisation against Drugs--266872.20 (--)High riskDerks, 2018 \[[@CR57]\]Germany2011--2014Current injectors in 8 German cities--131864.60 (--)Low riskTarjan, 2017 \[[@CR58]\]Hungary2011 and 2014PWID injecting in the last month and attending SEPs or drug treatment centres--36565.00 (--)Low riskHandanagic, 2016 \[[@CR59]\]CroatiaNovember 2014--February 2015PWID in the cities of Zagreb, Split and Rijeka--39938.30 (31.40--44.30)Low riskKaberg, 2017 \[[@CR60]\]Sweden7 April 2013--16 October 2014PWID in the Stockholm needle exchange program (NEP)39.3(1)138682.00 (--)High riskKeegan, 2017 \[[@CR61]\]Ireland31 January 2015Patients attending agonist opioid treatment in a clinic in Dublin50.2(18.3)22863.60 (--)High riskSkocibusic, 2016 \[[@CR62]\]Bosnia and Herzegovina--PWID of both sexes included in opiate substitution treatment in the southern part of Bosnia and Herzegovina--12052.50 (--)High riskSvendsen, 2017 \[[@CR63]\]NorwaySeptember 2015--November 2016PWID in local opioid substitution clinic and day centres in Trondheim, Norway--30441.00 (--)High riskNosotti, 2016 \[[@CR64]\]Italy--IDU sample in Rome--26141.70 (--)High risk

Comparison analysis {#Sec18}
-------------------

Pooled estimates by population and by country based on the results of quality assessment were shown in Table [5](#Tab5){ref-type="table"}. Compared with the results reported in previous systematic reviews, our results updated the prevalence in Czech Republic, Poland, Portugal among the general population, Sweden and Spain among pregnant women, the Netherlands, the UK and France among MSM, France, Spain, Germany, Sweden and Bosnia and Herzegovina among PWID. Among the general population, the updated estimates were lower than previous ones in most available countries. A significant decrease in anti-HCV prevalence was shown in Italy (1.37% vs. 5.90%).Table 5Estimates of anti-HCV prevalence by population and by countryCountryIncluded referencesSelected referencesSample sizeAnti-HCV prevalence (%) (95% CI)Baseline sample sizeBaseline prevalence (%) (95% CI)General population Spain3Single low risk136780.8 (0.65--0.95) \[[@CR20]\]3641.1(0.3--2.8) \[[@CR17]\] Italy2Pooled low risk124441.37 (1.17--1.58) \[[@CR22], [@CR23]\]48265.9(5.2--6.6) \[[@CR17]\] Poland2Single high risk618051.5 (1.4--1.6) \[[@CR24]\]---- Czech Republic1Single low risk30001.67 (1.21--2.13) \[[@CR27]\]---- Portugal1Single low risk16270.54 (0.18--0.9) \[[@CR28]\]---- Netherlands1Single high risk60360.56 (0.37--0.75) \[[@CR33]\]40460.1(0.0--0.2) \[[@CR17]\] Ireland1Single low risk37950.98 (0.67--1.29) \[[@CR26]\]14780.1(0.0--0.4) \[[@CR17]\]Pregnant women UK2Single low risk314670.1 (0.06--0.13) \[[@CR31]\]1106211 \[[@CR17]\] Slovenia1Single low risk318490.13 (0.09--0.17) \[[@CR32]\]904.4 \[[@CR17]\] Italy1Single high risk51840.2 (0.08--0.32) \[[@CR33]\]108811.7 (1.4--1.9) \[[@CR17]\] Poland1Single low risk383090.76 (0.67--0.85) \[[@CR34]\]15340.1 (0.0--0.3) \[[@CR17]\] Sweden1Single low risk41120.27 (0.11--0.43) \[[@CR35]\]---- Spain1Single low risk213790.55 (0.45--0.65) \[[@CR36]\]----First-time blood donors Italy1Single low risk19346120.09 (0.08--0.09) \[[@CR37]\]--0.094 (0.085--0.104) \[[@CR17]\] Greece1Single high risk38389190.03 (0.03--0.03) \[[@CR38]\]--1.202 (1.114--1.295) \[[@CR17]\]MSM Netherlands1Single high risk4397.1 (4.69--9.51) \[[@CR40]\]---- UK1Single low risk11401.8 (1.03--2.57) \[[@CR39]\]---- France1Single low risk130515.1 (4.72--5.48) \[[@CR41]\]----Prisoner UK2Pooled high risk14847.9 (6.53--9.28) \[[@CR42], [@CR43]\]545017.7(16.4--18.4) \[[@CR18]\] Portugal2Pooled high risk8216.51 (8.42--24.6) \[[@CR44], [@CR45]\]15134.4(26.9--42.6) \[[@CR18]\] Norway1Single high risk6251.6 (39.06--64.14) \[[@CR63]\] Spain1Single high risk43616 (12.55--19.45) \[[@CR47]\]--22.7(18.3--27.1) \[[@CR18]\]PWID UK3Pooled low risk181836.5 (34.29--38.72) \[[@CR48]--[@CR50]\]314449.1 (47.4--50.9) \[[@CR18]\] France2Pooled low risk301557.26 (55.49--59.02) \[[@CR53], [@CR54]\]---- Spain2Single low risk75472 (68.79--75.21) \[[@CR52]\]---- Greece2Pooled high risk309969.67 (68.05--71.29) \[[@CR55], [@CR56]\]130968.1 (65.5--70.6) \[[@CR18]\]Germany1Pooled low risk from a single study152666.18 (63.8--68.55) \[[@CR57]\]---- Italy1Single high risk26147.1 (41.03--53.17) \[[@CR64]\]74360.5 (56.8--64.0) \[[@CR18]\] Hungary1Single low risk75548.24 (44.67--51.81) \[[@CR58]\]65224.1 (20.8--27.6) \[[@CR18]\] Croatia1Pooled low risk from a single study83034.04 (30.81--37.26) \[[@CR59]\]20044 (37.0--51.2) \[[@CR18]\] Sweden1Single high risk138682 (79.98--84.02) \[[@CR60]\]---- Ireland1Single high risk22863.6 (57.34--69.86) \[[@CR61]\]20041.5 (34.6--48.7) \[[@CR18]\] Bosnia and Herzegovina1Single high risk12052.5 (43.53--61.47) \[[@CR62]\]---- Norway1Single high risk30441 (35.46--46.54) \[[@CR63]\]634263.0 (61.8--64.2)

Except for the Netherlands (0.56% vs. 0.10%) and Ireland (0.98% vs. 0.10%), prevalence increased. The same results were reported among high-risk populations, where prevalence in most countries decreased, except for the estimates among PWID in Hungary (48.24% vs. 24.10%).

Discussion {#Sec19}
==========

This review is the first one to integrate and contrast prevalence estimates across the general population and 3 key high-risk groups in the EU/EEA. This review describes the finding of 46 publications estimating anti-HCV prevalence from 17 of the 34 EU/EEA countries, with 11 publications focusing on the general population, 7 on pregnant women, 2 on first-time blood donors, 3 on MSM, 6 on prisoners and 17 on PWID. In total, 48 estimates for anti-HCV prevalence were included, with 11 estimates of the general population, 7 estimates of pregnant women, 2 estimates of first-time blood donors, 5 estimates of MSM, 6 estimates of prisoners and 17 estimates of PWID. The anti-HCV prevalence varies widely between countries and populations.

For the majority of countries, the availability of estimates on the anti-HCV prevalence is limited. The estimates were reported in half of EU/EEA countries (17 of the 34). The results of quality assessment show there are potentially high risk of selection bias in half of available estimates (24 of the 48). The lack of low risk of selection bias prevalence estimates makes it challenging to gain an overview of the current epidemiological burden in the EU/EEA, especially in two high-risk groups, MSM and prisoners, with only 5 and 6 estimates included. Out of the stigma and reputational concerns, the access to MSM population is limited. The participation rate of screening in prison was high; however, the use of self-reported behavioral data and low sensitivity and specificity of laboratory test resulted in the limited inclusion of studies in prison environment.

This review confirms the diversity in anti-HCV prevalence among different populations. Compared with the prevalence among the general population, prevalence among first-time blood donors and pregnant women were found to be considerably lower, which agrees with the previous result that they are not a reliable proxy population to estimate prevalence in the general population. The prevalence among MSM, prisoners and PWID were found to be much higher than the corresponding prevalence in the general population. Of the high-risk groups considered, PWID reported the highest prevalence.

In contrast with most published systematic reviews, this study updates and adds new estimates of anti-HCV prevalence for three countries in the general population (Czech Republic, Poland and Portugal), for 2 countries in pregnant women (Spain and Sweden), for one country in MSM (the Netherlands), for one country in prisoners (Norway) and for 5 countries in PWID (Bosnia and Herzegovina, France, Germany, Spain and Sweden). Compared with previous estimates, the current estimates on prevalence among both the general and high-risk populations decreased in most available countries. While, the estimates of prevalence in the Netherlands \[[@CR29]\] and Ireland \[[@CR26]\] among the general population and in Hungary among PWID \[[@CR58]\] increased. These estimates were all from single studies, and there may be a potential risk of selection bias. The estimate in the Netherlands was from a cohort consisting of more than 45-year-old elderly participants (mean age: 69.5 years) \[[@CR29]\], which may lead to the relatively higher estimates than previous study (age of range: 15--44 years) \[[@CR65]\]. The estimate in Ireland was from individuals whose specimens were submitted to the National Virus Reference Laboratory for diagnostic purpose, antenatal screening and pre-employment screening with most specimens being identified in older adults \[[@CR26]\]. This was not likely to be completely representative of the general adult population and consequently led to higher estimates of prevalence. The estimate in Hungary was conducted among PWID attending drug treatment centres between 2011 and 2015 \[[@CR58]\]. Since 2011, new psychoactive substances (NPS) have largely replaced traditionally injected drugs in Hungary \[[@CR66]\]. NPS are unregulated products and have been associated with increases in injecting risks and HCV infection \[[@CR66], [@CR67]\]. High-risk environments for PWID may have played an important role in the increase of HCV prevalence in Hungary, especially for NPS injectors \[[@CR68], [@CR69]\]. Another systematic review \[[@CR70]\] reported the anti-HCV prevalence for the 20 WHO European Region countries outside the EU/EEA. The anti-HCV prevalence outside the EU/EEA was higher than inside the EU/EEA among the general population (0.50--13.00% vs. 0.54 to 1.50%), and first-time blood donors (0.03--6.40% vs. 0.03--0.09%), but lower among PWID (5.30--73.00% vs. 7.90--82.00%).

The strength of this review is that it covers all the general population and high-risk groups. The previous reviews, due to pragmatic reasons, extracted prevalence estimates for PWID from the data repository from the ECDDA. It is possible that this data set is not exhaustive. In our review update, however, PWID-specific search terms were used to identify potential studies. We believe that the description provided gives a sufficiently thorough review of recently published anti-HCV prevalence estimates. With the latest prevalence estimates, this study can contribute to the analyses in cost of illness, cost-effectiveness and budget impact to optimise the healthcare resource utilisation in hepatitis C management and a HCV eradication program in Europe. The fundamental approaches to control a HCV epidemic are prevention of new infections and management of existing infections. Currently, there is no vaccine for the prevention of the HCV infection. A needle/syringe provision (NSP) and opioid substitution treatment (OST) as the main primary prevention strategy and HCV antiviral treatment as a treatment-as-prevention strategy are the key components to reduce HCV prevalence. Several studies have shown that high coverage of NSP and OST \[[@CR71]--[@CR74]\] and scaling up HCV treatment, especially treatment with DAAs that possess high efficacy and improved safety profiles \[[@CR11], [@CR13], [@CR14], [@CR75]\], can lead to substantial reductions in anti-HCV prevalence. The use of DAAs could make hepatitis C a rare disease in the next 20 to 30 years \[[@CR76]\]. Despite advances in prevention and treatment, the HCV related disease burden is expected to increase before it starts declining, as well as corresponding healthcare cost \[[@CR77]\]. This highlights the importance of optimisation of resource allocation in HCV eradication program.

However, this study confirmed that there was an evidence gap on anti-HCV prevalence among lots of EU/EEA countries. This limitation of this study also provides the idea for further research. In some countries, no national studies had been reported, thus local and regional data were assumed to be reflective of the whole country. However, by assessing the methodological quality of the studies, this limitation can be further mitigated.

Conclusion {#Sec20}
==========

This review emphasises the heterogeneity in anti-HCV prevalence across different population groups in Europe. The prevalence also shows considerable diversity between EU/EEA countries. There are many countries that are not described in our results, emphasising the existing need to develop robust epidemiological studies.

Additional file
===============
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Additional file 1:Methodological details of study. 1.1 Search strategy for studies in Medline and Embase via Ovid; 1.2 Inclusion and exclusion criteria; 1.3 Results of quality assessment for risk of selection bias. (DOCX 95 kb)
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